Stergios J. Moschos, MD, an associate professor of medicine in the Department of Medicine in the Division of Oncology at the University of North Carolina (UNC) Chapel Hill School of Medicine, UNC Health, emphasized the importance of appropriately administering bridging therapy to patients who are slated to receive the adoptive T-cell therapy lifileucel (Amtagvi).
2025
Patient Selection Is Crucial for Treatment Decisions in Metastatic Melanoma After PD-1 Inhibition
Stergios Moschos, MD, discusses his approach to selecting from the available agents in metastatic melanoma after first-line PD-1 inhibition.
Comparing Melanoma Immunotherapy Outcomes in Key Clinical Trials
During a live event, Ahmad Tarhini, MD, PhD, discussed key melanoma trials with varying survival and toxicity profiles.
This article is part 1 of a 2-part series from a Case-Based Roundtable event.
PBAF chromatin may explain melanoma spread to the brain
Scientists at the Icahn School of Medicine at Mount Sinai have discovered a possible reason why some cases of melanoma—a dangerous form of skin cancer—spread to the brain. Their study, published in Molecular Cell, highlights the role of a group of proteins called the PBAF chromatin remodeling complex in keeping melanoma from getting worse.